Answers are grounded in this paper and cite their sources.
Objectives: The objective of this Phase 2 study was to determine the safety and efficacy of QTORIN rapamycin 3.9% anhydrous gel for the treatment of cutaneous microcystic lymphatic malformations (LM). Design: The study was a multicenter, baseline-controlled Phase 2 clinical trial. Setting: The study was performed at 5 clinical sites in the United States. Participants: Participants were ≥6 years old with a clinical diagnosis of cutaneous microcystic LM. Intervention: Participants self-administered topical QTORIN rapamycin once daily for 12 weeks. Main Outcome Measurements: Outcomes were measured via standardized clinician- and patient-reported outcomes, including clinician global impression of change, clinician global impression of severity (CGI-S), patient global impression of severity, patient global impression of change (PGI-C), as well as lesion leaking or bleeding, thickness/height/size of lesion, LM symptom severity scale, dermatology life quality index, and overall patient satisfaction. Results: Safety, clinical examinations, laboratory evaluations, and quantification of sirolimus blood levels, suggested that QTORIN rapamycin was generally safe and well-tolerated. Efficacy indicated statistically significant improvements in endpoints with treatment. Clinician and patient reports were supported by visual photographs showing significant improvement in lesions over the course of treatment. Conclusions: This Phase 2 study provides compelling evidence of the safety and efficacy of QTORIN rapamycin, a novel 3.9% topical sirolimus formulation, for the treatment of microcystic LM and supports further development including a larger trial in this patient population.
No takes yet. Share an insight, caveat, or question.
Treat et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: